This role is considered Hybrid.             Overview   We are seeking a scientist to join our R&D based RNA Sequencing team. Our mission is to enable various transcriptomics techniques to aid pre-clinical evaluation of siRNA-based therapeutics and advancement of our clinical pipeline. Our passion is to make transcriptomics approachable and expand its utility in drug discovery by pushing boundaries of scale, methodology, automation, data interpretation.   A candidate should be able to work through across wet, dry NGS techniques and examine data biology. Such a background and an experience in NGS, molecular biology, biology and data analysis/coding/computer science are desired. But most of all a successful candidate should be a highly motivated, proactive, open-minded problem solver with an appetite for method and application development.   Summary of Key Responsibilities   * Support advanced transcriptomics techniques like, single cell, spatial, long read transcriptomics studies through design, sample and library generations, data analysis; continue to improve techniques and data analysis toolbox * Data mining and interpretation; identification or development of custom bioinformatic tools to address custom technical and biological questions; written and oral reports preparations * Act as the subject matter expert and continuously drive technologies and applications development to expand capabilities * Support general lab operation ex., troubleshooting technical problems, training and mentoring junior lab members * Adapts well to the changing platform needs, in workflow, projects and other tasks as required by the pipeline.   Qualifications   * MS in a biological and/or computer science related disciplines with 5+ or PhD with 0-3 years of relevant experience * Familiarity with NGS wet and dry lab techniques * Self-starter, self-learner, intensely detail oriented and curious mindset * Excellent time management and organizational skills, ability to multitask and work cross functionally     About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.   Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.   At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.